Neuron-AFib SIGNED
Commercialising cardiac autonomic modulation to treat Atrial Fibrillation
Total Cost €
0EC-Contrib. €
0Partnership
0Views
0Neuron-AFib project word cloud
Explore the words cloud of the Neuron-AFib project. It provides you a very rough idea of what is the project "Neuron-AFib" about.
Project "Neuron-AFib" data sheet
The following table provides information about the project.
| Coordinator |
ATRIAN MEDICAL LIMITED
Organization address contact info |
| Coordinator Country | Ireland [IE] |
| Total cost | 3˙358˙205 € |
| EC max contribution | 2˙348˙941 € (70%) |
| Programme |
1. H2020-EU.3. (PRIORITY 'Societal challenges) 2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs) 3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies) |
| Code Call | H2020-SMEInst-2018-2020-2 |
| Funding Scheme | SME-2 |
| Starting year | 2019 |
| Duration (year-month-day) | from 2019-11-01 to 2022-04-30 |
Partnership
Take a look of project's partnership.
| # | ||||
|---|---|---|---|---|
| 1 | ATRIAN MEDICAL LIMITED | IE (GALWAY) | coordinator | 2˙348˙941.00 |
Map
Project objective
Atrial Fibrillation (AFib) is a debilitating and life-threatening condition with a high and increasing prevalence worldwide. However current treatments have low success rates and have significant risks and complications. Moreover, the most widely used treatment – cardiac ablation - still has limited adoption with the majority of patients hesitant to be treated knowing the potential for poor outcomes and complications. In addition, current treatments have even lower success rates and higher complications in women.
AtriAN Medical is bringing a revolutionary treatment to market that is the first to specifically target the origin of the signal that causes AFib, thus eliminating the arrhythmia and disease progression. In addition to increased success rates, the AtriAN technology will reduce the risk of complications and the procedure will be done in a fraction of the time needed for current treatments; approximately 2 hours compared to 6-8 hours. The treatment will work equally well in women and men. AtriAN conservatively estimates that it will have turnovers of €85M per annum within one year of regulatory approvals. AtriAN has a senior management team in place with significant medical device industry experience in technology development, manufacturing and scale up from start-up to multinational size.
AtriAN needs to perform a clinical trial in order to gain CE-marking to allow sales in Europe. AtriAN is planning for CE approvals by 2022 and FDA approval by 2026.
The proposed Neuron AFib project will first finalise the device testing and validation needed in order to meet regulatory requirements and will then perform the clinical trial, with equal female and male enrolment, in order to demonstrate safety and efficacy of the treatment. AtriAN has already raised €3.8 million of funds needed to close out research activities but needs another €2.4 million to execute on the testing, validation and clinical trial needed to reach CE approval and commercial launch.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "NEURON-AFIB" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "NEURON-AFIB" are provided by the European Opendata Portal: CORDIS opendata.